(Q37224111)

19 August 2017

JAK mutations in high-risk childhood acute lymphoblastic leukemia (English)

1 reference

19 August 2017

1 reference

lymphoblastic leukemia

1 reference

Richard C Harvey

3

0 references

Sarah K. Tasian

Sarah K Tasian

7

0 references

Charles G. Mullighan

Charles G Mullighan

1

0 references

Stephen P Hunger

20

Stephen P Hunger

1 reference

19 August 2017

21

Cheryl L Willman

1 reference

19 August 2017

8

Mignon L Loh

1 reference

19 August 2017

18

Malcolm Smith

1 reference

19 August 2017

17

Gregory H Reaman

1 reference

19 August 2017

15

Daniela S Gerhard

1 reference

19 August 2017

6

Letha A Phillips

1 reference

J Racquel Collins-Underwood

19 August 2017

4

J Racquel Collins-Underwood

1 reference

19 August 2017

Jinghui Zhang

2

1 reference

19 August 2017

Brenda A Schulman

5

1 reference

19 August 2017

Xiaoping Su

9

1 reference

19 August 2017

Wei Liu

10

1 reference

19 August 2017

Meenakshi Devidas

11

1 reference

19 August 2017

Susan R Atlas

12

1 reference

19 August 2017

I-Ming Chen

13

1 reference

19 August 2017

Robert J Clifford

14

1 reference

19 August 2017

William L Carroll

16

1 reference

19 August 2017

James R Downing

19

1 reference

19 August 2017

language of work or name

English

0 references

publication date

22 May 2009

1 reference

Proceedings of the National Academy of Sciences of the United States of America

19 August 2017

1 reference

19 August 2017

106

1 reference

19 August 2017

9414-9418

1 reference

19 August 2017

23

1 reference

Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia

19 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2695045

JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2695045

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2695045

Jak2 FERM domain interaction with the erythropoietin receptor regulates Jak2 kinase activity

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2695045

Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2695045

Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2695045

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2695045

A gain-of-function mutation of JAK2 in myeloproliferative disorders

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2695045

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2695045

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2695045

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2695045

The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2695045

Involvement of Jak2 tyrosine phosphorylation in Bcr-Abl transformation

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2695045

Crystal structure of the complex of the cyclin D-dependent kinase Cdk6 bound to the cell-cycle inhibitor p19INK4d

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2695045

Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2695045

Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2695045

Evaluation of survival data and two new rank order statistics arising in its consideration

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2695045

Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2695045

Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2695045

Janus kinase 2: a critical target in chronic myelogenous leukemia

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2695045

JAK1 and Tyk2 activation by the homologous polycythemia vera JAK2 V617F mutation: cross-talk with IGF1 receptor.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2695045

Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2695045

Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2695045

The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2695045

Classification of pediatric acute lymphoblastic leukemia by gene expression profiling

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2695045

BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2695045

Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling

4 December 2018

1 reference

12 December 2020

Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy

1 reference

12 December 2020

Acute lymphoblastic leukaemia

1 reference

12 December 2020

Myeloproliferative disorders

1 reference

12 December 2020

Identifiers

DOI

10.1073/PNAS.0811761106

1 reference

19 August 2017

0 references

1 reference

19 August 2017

1 reference